SNP information rs8099917

Research and publications:

  19749757   Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

  19749758   IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

  20060832   Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

  20184973   Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle

  20434452   Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C

  20576307   Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients

  20648473   Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

  20708617   Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C

  20728570   Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C

  20729732   Host genetic basis for hepatitis C virus clearance: a role for blood collection centers

  20803561   Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

  20931559   IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C

  20950615   IL28B and the control of hepatitis C virus infection

  21048934   IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

  21068134   HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

  21080244   The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection

  21112657   Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

  21112660   Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b

  21145800   IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy

  21145807   Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin

  21147189   IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway

  21228123   IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations

  21246582   Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

  21254157   Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

  21274371   Peginterferon and ribavirin treatment for hepatitis C virus infection

  21303914   Interferon lambdas: the next cytokine storm

  21321200   Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

  21325786   Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment

  21345258   Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

  21346780   IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

  21354446   IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C

  21360545   Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b

  21360716   Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance

  21374656   IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

  21382156   Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment

  21384511   Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

  21389156   The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with inter

  21390311   Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

  21466653   Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation

  21479134   IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

  21501223   Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients

  21503910   Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

  21567424   Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C

  21613433   Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients

  21628662   IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

  21692944   IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1

  21694902   New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

  21703176   Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

  21703198   Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

  21704279   Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response

  21721028   Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

  21722179   Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data

  21739446   Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene

  21745312   Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy

  21820962   Interferon-lambda and therapy for chronic hepatitis C virus infection

  21879313   Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C

  21884576   Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

  21889215   IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis

  21898478   Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

  21900787   A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus

  21907615   Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin

  21911885   Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin

  21914076   IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

  21931540   IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

  21987611   IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients

  22003405   IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy

  22013224   IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association

  22032680   Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determi

  22046316   Genetic variation of the IL-28B promoter affecting gene expression

  22052088   Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection

  22087138   Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B

  22095536   Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b

  22098416   IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population

  22098610   Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C

  22110669   Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort

  22118055   Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

  22180014   IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

  22180419   IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection

  22192885   Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection

  22193282   Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1

  22209781   Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese

  22214245   Genomics and proteomics in liver fibrosis and cirrhosis

  22234924   Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection

  22239510   Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection

  22245236   Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection

  22253715   Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3

  22253847   Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients

  22275900   Pharmacogenomics: what is next?

  22301466   Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy

  22310928   Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma

  22314430   IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease

  22325058   Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population

  22328925   Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients

  22329371   IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection

  22345656   IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5

  22350701   IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients

  22356575   The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy

  22368681   The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

  22374338   Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis